Guardant Health, Foundation Medicine reach settlement

By LabPulse.com staff writers

January 10, 2022 -- Precision oncology company Guardant Health and Foundation Medicine have agreed to settle pending litigation concerning Guardant patents for digital sequencing technology.

Under terms of the agreement, Foundation Medicine will pay Guardant Health $25 million and future royalties for the remaining term of the licensed patents. In exchange, Guardant Health will grant Foundation Medicine a nonexclusive license to a subset of its digital sequencing technology patents.

The agreement dismisses all pending patent litigation between Foundation Medicine and Guardant Health, according to Guardant.

Guardant initiates study of its liquid biopsy test
Precision oncology company Guardant Health has initiated a study to evaluate its Guardant Reveal blood test, a liquid biopsy to predict the recurrence...
Lunit receives $26M funding from Guardant Health
South Korean artificial intelligence (AI) software developer Lunit recently announced a strategic investment of $26 million from Guardant Health....
Natera and Guardant Health embroiled in legal battle
Cell-free DNA testing company Natera and oncology firm Guardant Health have filed dueling false-advertising legal claims over oncology diagnostic tests.
Guardant touts data presented at SABCS
Guardant Health has touted research presented at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) demonstrating how its tools benefit women...
Seoul researchers tout Guardant360 clinical results
South Korean researchers highlighted clinical results from a study that used precision oncology company Guardant Health's Guardant360 test in patients...

Copyright © 2022 LabPulse.com

Last Updated ls 1/10/2022 3:59:58 PM